This early-stage trial tests a new inhaled nitric oxide treatment (RESP30X) in 60 adults with non-cystic fibrosis bronchiectasis who have stubborn lung infections like Pseudomonas. The main goals are to check safety and how well the body tolerates the mist, while also seeing if i…
Phase: PHASE1, PHASE2 • Sponsor: Thirty Respiratory Limited • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC